Attenuating mutations in Venezuelan Equine Encephalitis virus
AssigneeThe University of North Carolina at Chapel Hill
InventorsRobert E. Johnston, Nancy L. Davis, Jonathan F. Smith, Franziska B. Grieder
Life of this patent
Estimating the term…
Abstract
Novel attenuating mutations of Venezuelan Equine Encephalitis (VEE) are disclosed. Further aspects of the invention include an infectious VEE virus transcript encoded by cDNA clones, infectious VEE virus particles, and pharmaceutical formulations containing such infectious particles. Also disclosed are recombinant VEE virus containing a heterologous RNA segment.
Claims11
A DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a heterologous promoter positioned upstream from said cDNA clone and operatively associated therewith, and further comprising at least one attenuating mutation selected from the group consisting of codons at E1 amino acid 272 which specify an attenuating mutation;
- and codons at E1 amino acid 253 which specify an attenuating mutation.
A DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a heterologous promoter positioned upstream from said cDNA clone and operatively associated therewith, and further comprising:
- a first attenuating mutation which is a codon at E1 amino acid 253 which specifies an attenuating mutation;
- and
- a second mutation which is an inactivated E3 amino acid 56 to 59 cleavage recognition site.
Dependencies are inferred from the claim text.